Asuragen Revenue and Competitors

Asuragen, Inc. is a newly formed company that resulted from the sale, in March, 2006, of the Research Products Division of Ambion, Inc. to Applied Biosystems Group (NYSE: ABI). Asuragen is comprised of two of Ambion's former divisions, Diagnostics and Services, along with the formation of a new Discovery group dedicated to developing new technologies that will become cutting edge clinical products. This will significantly expand Asuragen's current product portfolio, which consists of Signature(R) Genetic Testing and Oncology Testing products, as well as industry leading controls and standards engineered using its patented Armored RNA(R) technology. Asuragen has recently formed a partnership with Digene Corporation (NASDAQ: DIGE) to market and distribute its Signature cystic fibrosis screening products. The vision for Asuragen is to become a fully integrated diagnostic reagent company focused on molecular oncology and early detection of cancer, with emphasis in microRNAs. Comprised of over 100 employees from a well-established company, Asuragen is empowered with not only scientific expertise, but also assay development, business infrastructure and an established cGMP manufacturing facility that allow it to span the spectrum of discovery, production and commercialization.

keywords:Biotechnology